Akademik Veri Yönetim Sistemi
FOOD BIOSCIENCE, cilt.75, 2026 (SCI-Expanded, Scopus)
Inflammatory and immune-related pathways act as a central mediator in the pathogenesis of a wide range of diseases, including cancer, cardiovascular diseases, kidney disorders, acute lung injury, autoimmune conditions, and neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. The activation of the NACHT, LRR and PYD domain-containing protein 3 (NLRP3) inflammasome, a key component of innate immunity, promotes inflammation through the release of interleukin (IL)-18. By enhancing the production of other pro-inflammatory cytokines like interferon (IFN)-gamma and facilitating T-helper cell polarization, IL-18 amplifies the inflammatory cascade. Research indicates that curcumin effectively suppresses IL-18 production and modulates signaling pathways that contribute to its activation, including the nuclear factor kappa B (NF-kappa B) and NLRP3 inflammasome pathways. NF-kappa B, a master regulator of inflammation, is directly influenced by curcumin, which inhibits its translocation to the nucleus, thereby downregulating the expression of IL-18 and other inflammatory mediators. By targeting upstream regulators and components of the inflammasome, curcumin reduces pyroptosis, oxidative stress, and cytokine storm-like responses, offering a multifaceted therapeutic approach. The role of curcumin in modulating oxidative stress and immune responses positions it as a promising adjunct or alternative therapeutic agent for diseases linked to IL-18 dysregulation. Preclinical and clinical studies have further demonstrated synergistic effects when combined with conventional therapies. This highlights its potential not only in mitigating disease progression but also in addressing underlying inflammatory processes such as chronic inflammatory disease, cardiovascular disease, and neurodegenerative disease. Given these attributes, targeting IL-18 with curcumin-based interventions is the way for novel therapeutic strategies that balance efficacy with minimal side effects, addressing both symptoms and underlying disease mechanisms.